AR021896A1 - Sulfoniloxazolaminas como sustancias activas terapeuticas, un procedimiento para su preparacion, su empleo como sustancias activas terapeuticas y/o parapreparar composiciones farmaceuticas, las composiciones farmaceuticas que las contienen y un procedimiento para preparar estas composiciones farmace - Google Patents
Sulfoniloxazolaminas como sustancias activas terapeuticas, un procedimiento para su preparacion, su empleo como sustancias activas terapeuticas y/o parapreparar composiciones farmaceuticas, las composiciones farmaceuticas que las contienen y un procedimiento para preparar estas composiciones farmaceInfo
- Publication number
- AR021896A1 AR021896A1 ARP990106528A ARP990106528A AR021896A1 AR 021896 A1 AR021896 A1 AR 021896A1 AR P990106528 A ARP990106528 A AR P990106528A AR P990106528 A ARP990106528 A AR P990106528A AR 021896 A1 AR021896 A1 AR 021896A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical compositions
- active therapeutic
- therapeutic substances
- preparation
- sulfonyloxazolamins
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 2
- 239000000126 substance Substances 0.000 title 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- HVISAPYMDYXBIV-UHFFFAOYSA-N 2-(sulfonylamino)-1,3-oxazole Chemical class O=S(=O)=NC1=NC=CO1 HVISAPYMDYXBIV-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Sulfoniloxazolaminas como sustancias activas terapéuticas, que responden a la formula general (1) en donde R1 y R2 representan independientemente H, A,cicloalquilo C3-8, -(CH2)n-Ar, -(CH2)n-OA, -(CH2)n-NH2, -(CH2)n-NA2 o alquenilo de 2 a 6 átomos deC, R1 y R2 juntos, también forman un heterociclosaturado de un solo nucleo que tiene 1 a 2 átomos de N, O y/o S, Z, Z1 o Z2 representan independientementeH, A, CF3, NO2, Hal, OH, OA, OCF3, SCF3, NH2,NHA o NA2, A representa alquilo de 1 a 6 átomos deC, Ar representa fenilo-mono, di o trisustituido con Z, Hal representa F, Cl, Br o I, n es 1,2,3 o 4, o sussales aceptables desde el punto de vista fisiologico o sus solvatos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19858593A DE19858593A1 (de) | 1998-12-18 | 1998-12-18 | Sulfonyloxazolamine als therapeutische Wirkstoffe |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR021896A1 true AR021896A1 (es) | 2002-08-07 |
Family
ID=7891645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990106528A AR021896A1 (es) | 1998-12-18 | 1999-12-17 | Sulfoniloxazolaminas como sustancias activas terapeuticas, un procedimiento para su preparacion, su empleo como sustancias activas terapeuticas y/o parapreparar composiciones farmaceuticas, las composiciones farmaceuticas que las contienen y un procedimiento para preparar estas composiciones farmace |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6441013B1 (es) |
| EP (1) | EP1140875A1 (es) |
| JP (1) | JP2002533332A (es) |
| CN (1) | CN1146549C (es) |
| AR (1) | AR021896A1 (es) |
| AU (1) | AU763070B2 (es) |
| BR (1) | BR9916310A (es) |
| CA (1) | CA2356134A1 (es) |
| CZ (1) | CZ20012144A3 (es) |
| DE (1) | DE19858593A1 (es) |
| HK (1) | HK1043125A1 (es) |
| HU (1) | HUP0104834A3 (es) |
| ID (1) | ID29966A (es) |
| NO (1) | NO20012965L (es) |
| PL (1) | PL349393A1 (es) |
| RU (1) | RU2232757C2 (es) |
| SK (1) | SK8132001A3 (es) |
| WO (1) | WO2000037452A1 (es) |
| ZA (1) | ZA200105881B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19956791A1 (de) * | 1999-11-25 | 2001-05-31 | Merck Patent Gmbh | Neue Sulfonyloxazolamine |
| DE10129940A1 (de) * | 2001-06-13 | 2002-12-19 | Merck Patent Gmbh | Sulfonyloxazolamine als therapeutische Wirkstoffe |
| US6875771B2 (en) * | 2002-07-26 | 2005-04-05 | Bristol-Myers Squibb Company | Pyridopyrimidine derivatives as 5-HT6 antagonists |
| FR2854632B1 (fr) * | 2003-05-07 | 2005-06-17 | Centre Nat Rech Scient | Synthese de composes heterocycliques substitues |
| GB0419192D0 (en) * | 2004-08-27 | 2004-09-29 | Merck Sharp & Dohme | Therapeutic agents |
| PL1831159T3 (pl) * | 2004-12-21 | 2010-06-30 | Hoffmann La Roche | Pochodne tetraliny i indanu oraz ich zastosowania |
| WO2007016979A2 (en) * | 2005-07-29 | 2007-02-15 | 4Sc Ag | NOVEL HETEROCYCLIC NF-κB INHIBITORS |
| DE102005061429A1 (de) * | 2005-12-22 | 2007-06-28 | Grünenthal GmbH | Substituierte Oxazol-Derivate |
| US8394788B2 (en) * | 2006-11-16 | 2013-03-12 | The Regents Of The University Of California | Phenylsulfoxyoxazole compound inhibitors of urea transporters |
| WO2008092785A1 (en) * | 2007-02-02 | 2008-08-07 | F. Hoffmann-La Roche Ag | Novel 2-aminooxazolines as taar1 ligands for cns disorders |
| KR101222412B1 (ko) * | 2007-02-15 | 2013-01-15 | 에프. 호프만-라 로슈 아게 | Ｔａａｒ1 리간드로서의 2-아미노옥사졸린 |
| CN102481794B (zh) | 2009-12-28 | 2014-12-10 | 兄弟工业株式会社 | 带盒 |
| RU2443697C1 (ru) | 2010-12-21 | 2012-02-27 | Александр Васильевич Иващенко | Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения |
| WO2018012769A1 (ko) * | 2016-07-12 | 2018-01-18 | 연세대학교 산학협력단 | 자가포식 향상물질 및 그 용도 |
| KR102533605B1 (ko) * | 2018-01-10 | 2023-05-17 | 주식회사 라이조테크 | 신규한 페닐설포닐 옥사졸 유도체 및 이의 용도 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2221692A1 (en) * | 1995-05-19 | 1996-11-21 | G.D. Searle & Co. | Substituted oxazoles for the treatment of inflammation |
| AU717230B2 (en) | 1996-02-20 | 2000-03-23 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
-
1998
- 1998-12-18 DE DE19858593A patent/DE19858593A1/de not_active Withdrawn
-
1999
- 1999-12-01 WO PCT/EP1999/009335 patent/WO2000037452A1/de not_active Ceased
- 1999-12-01 AU AU18612/00A patent/AU763070B2/en not_active Ceased
- 1999-12-01 HK HK02104944.7A patent/HK1043125A1/zh unknown
- 1999-12-01 ID IDW00200101555A patent/ID29966A/id unknown
- 1999-12-01 SK SK813-2001A patent/SK8132001A3/sk unknown
- 1999-12-01 CN CNB998147281A patent/CN1146549C/zh not_active Expired - Fee Related
- 1999-12-01 RU RU2001119273/04A patent/RU2232757C2/ru not_active IP Right Cessation
- 1999-12-01 BR BR9916310-1A patent/BR9916310A/pt not_active IP Right Cessation
- 1999-12-01 PL PL99349393A patent/PL349393A1/xx unknown
- 1999-12-01 CZ CZ20012144A patent/CZ20012144A3/cs unknown
- 1999-12-01 JP JP2000589524A patent/JP2002533332A/ja active Pending
- 1999-12-01 CA CA002356134A patent/CA2356134A1/en not_active Abandoned
- 1999-12-01 US US09/868,097 patent/US6441013B1/en not_active Expired - Fee Related
- 1999-12-01 EP EP99962190A patent/EP1140875A1/de not_active Withdrawn
- 1999-12-01 HU HU0104834A patent/HUP0104834A3/hu unknown
- 1999-12-17 AR ARP990106528A patent/AR021896A1/es not_active Application Discontinuation
-
2001
- 2001-06-15 NO NO20012965A patent/NO20012965L/no not_active Application Discontinuation
- 2001-07-17 ZA ZA200105881A patent/ZA200105881B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0104834A3 (en) | 2005-06-28 |
| CN1146549C (zh) | 2004-04-21 |
| AU1861200A (en) | 2000-07-12 |
| CN1331684A (zh) | 2002-01-16 |
| BR9916310A (pt) | 2001-11-06 |
| HK1043125A1 (zh) | 2002-09-06 |
| NO20012965D0 (no) | 2001-06-15 |
| HUP0104834A2 (hu) | 2002-07-29 |
| EP1140875A1 (de) | 2001-10-10 |
| SK8132001A3 (en) | 2002-02-05 |
| AU763070B2 (en) | 2003-07-10 |
| WO2000037452A1 (de) | 2000-06-29 |
| JP2002533332A (ja) | 2002-10-08 |
| NO20012965L (no) | 2001-06-15 |
| CA2356134A1 (en) | 2000-06-29 |
| DE19858593A1 (de) | 2000-06-21 |
| RU2232757C2 (ru) | 2004-07-20 |
| PL349393A1 (en) | 2002-07-15 |
| ID29966A (id) | 2001-10-25 |
| US6441013B1 (en) | 2002-08-27 |
| ZA200105881B (en) | 2002-10-17 |
| CZ20012144A3 (cs) | 2002-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR021896A1 (es) | Sulfoniloxazolaminas como sustancias activas terapeuticas, un procedimiento para su preparacion, su empleo como sustancias activas terapeuticas y/o parapreparar composiciones farmaceuticas, las composiciones farmaceuticas que las contienen y un procedimiento para preparar estas composiciones farmace | |
| AR003397A1 (es) | Bifenilamidas utiles para combatir hongos nocivos para las plantas, procedimiento para prepararlas, las composiciones que las contienen,procedimiento para prepararlas y los procedimientos de aplicacion | |
| AR026163A1 (es) | Utilizacion de retigabina para el tratamiento de dolores neuropaticos | |
| EA199900937A1 (ru) | Фармацевтические композиции, содержащие вориконазол | |
| PE20050012A1 (es) | Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2 | |
| DK0705254T3 (da) | Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer | |
| UY29919A1 (es) | Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones | |
| AR028914A1 (es) | 2-guanidino-4-aril-quinazolinas como inhibidores de nhe-3 | |
| DOP2003000765A (es) | Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer (substituted ureas and carbamates useful in the treatment of alzheimer`s disease | |
| AR013079A1 (es) | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios | |
| AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
| SV2003000741A (es) | Compuesto lactamico x-13170 | |
| SE0101322D0 (sv) | Novel compounds | |
| ES496038A0 (es) | Procedimiento para la obtencion de 2-hidroxialquil-3,4,5- trihidroxi-piperidinas | |
| CO5590934A2 (es) | Procedimiento de preparacion de derivados de equinocandina | |
| DK1250337T3 (da) | Substituerede homopiperidinylbenzimidazol-analoger som fundus-relaksanter | |
| ES2189072T3 (es) | Nuevo benzo-cicloalquenos heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| ES556352A0 (es) | Un procedimiento para preparar derivados de 5-oxo-1-imidazolidinacetamida | |
| BR0211425A (pt) | Método para a preparação de compostos, e, uso de uma composição | |
| NZ504706A (en) | Substituted isoquinoline derivatives and their use as anticonvulsants | |
| AR005549A1 (es) | Derivados de la 1-pirazol-3-iletil-4-indol-3-ilpiperidina, un procedimiento para prepararlos, medicamentos y preparaciones farmaceuticas que los contienen,un procedimiento para preparar las preparaciones farmaceuticas y empleo de los mismos para la preparacion de medicamentos. | |
| AR041317A1 (es) | Tratamiento pesticida de productos alimenticios almacenados, camaras,estructuras y obras de arte, con compuestos de azufre | |
| AR004718A1 (es) | Procedimiento para preparar bisindolilmaleimidas con un puente n,n', utiles como inhibidores de la proteina c quinasa y procedimiento para preparar compuestos intermediarios de aplicacion en dicho procedimiento | |
| DE69827614D1 (de) | Chinoxalindionen | |
| PT1347960E (pt) | Processo para a preparacao de (+)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |